Cargando…
World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
Antimicrobial resistance is a major public health problem globally. Likewise, forms of tuberculosis (TB) resistant to first- and second-line TB medicines present a major challenge for patients, healthcare workers and healthcare services. In November 2019, the World Health Organization (WHO) convened...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176349/ https://www.ncbi.nlm.nih.gov/pubmed/33243847 http://dx.doi.org/10.1183/13993003.03300-2020 |
_version_ | 1783703243664130048 |
---|---|
author | Mirzayev, Fuad Viney, Kerri Linh, Nguyen Nhat Gonzalez-Angulo, Licé Gegia, Medea Jaramillo, Ernesto Zignol, Matteo Kasaeva, Tereza |
author_facet | Mirzayev, Fuad Viney, Kerri Linh, Nguyen Nhat Gonzalez-Angulo, Licé Gegia, Medea Jaramillo, Ernesto Zignol, Matteo Kasaeva, Tereza |
author_sort | Mirzayev, Fuad |
collection | PubMed |
description | Antimicrobial resistance is a major public health problem globally. Likewise, forms of tuberculosis (TB) resistant to first- and second-line TB medicines present a major challenge for patients, healthcare workers and healthcare services. In November 2019, the World Health Organization (WHO) convened an independent international expert panel to review new evidence on the treatment of multidrug- (MDR) and rifampicin-resistant (RR) TB, using the Grading of Recommendations Assessment, Development and Evaluation approach. Updated WHO guidelines emerging from this review, published in June 2020, recommend a shorter treatment regimen for patients with MDR/RR-TB not resistant to fluoroquinolones (of 9–11 months), with the inclusion of bedaquiline instead of an injectable agent, making the regimen all oral. For patients with MDR-TB and additional fluoroquinolone resistance, a regimen composed of bedaquiline, pretomanid and linezolid may be used under operational research conditions (6–9 months). Depending on the drug-resistance profile, extent of TB disease or disease severity, a longer (18–20 months) all-oral, individualised treatment regimen may be used. In addition, the review of new data in 2019 allowed the WHO to conclude that there are no major safety concerns on the use of bedaquiline for >6 months’ duration, the use of delamanid and bedaquiline together and the use of bedaquiline during pregnancy, although formal recommendations were not made on these topics. The 2020 revision has highlighted the ongoing need for high-quality evidence and has reiterated the need for clinical trials and other research studies to contribute to the development of evidence-based policy. |
format | Online Article Text |
id | pubmed-8176349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-81763492021-06-07 World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update Mirzayev, Fuad Viney, Kerri Linh, Nguyen Nhat Gonzalez-Angulo, Licé Gegia, Medea Jaramillo, Ernesto Zignol, Matteo Kasaeva, Tereza Eur Respir J Task Force Report Antimicrobial resistance is a major public health problem globally. Likewise, forms of tuberculosis (TB) resistant to first- and second-line TB medicines present a major challenge for patients, healthcare workers and healthcare services. In November 2019, the World Health Organization (WHO) convened an independent international expert panel to review new evidence on the treatment of multidrug- (MDR) and rifampicin-resistant (RR) TB, using the Grading of Recommendations Assessment, Development and Evaluation approach. Updated WHO guidelines emerging from this review, published in June 2020, recommend a shorter treatment regimen for patients with MDR/RR-TB not resistant to fluoroquinolones (of 9–11 months), with the inclusion of bedaquiline instead of an injectable agent, making the regimen all oral. For patients with MDR-TB and additional fluoroquinolone resistance, a regimen composed of bedaquiline, pretomanid and linezolid may be used under operational research conditions (6–9 months). Depending on the drug-resistance profile, extent of TB disease or disease severity, a longer (18–20 months) all-oral, individualised treatment regimen may be used. In addition, the review of new data in 2019 allowed the WHO to conclude that there are no major safety concerns on the use of bedaquiline for >6 months’ duration, the use of delamanid and bedaquiline together and the use of bedaquiline during pregnancy, although formal recommendations were not made on these topics. The 2020 revision has highlighted the ongoing need for high-quality evidence and has reiterated the need for clinical trials and other research studies to contribute to the development of evidence-based policy. European Respiratory Society 2021-06-03 /pmc/articles/PMC8176349/ /pubmed/33243847 http://dx.doi.org/10.1183/13993003.03300-2020 Text en Copyright ©The authors 2021 https://creativecommons.org/licenses/by/4.0/This version is distributed under the terms of the Creative Commons Attribution Licence 4.0. |
spellingShingle | Task Force Report Mirzayev, Fuad Viney, Kerri Linh, Nguyen Nhat Gonzalez-Angulo, Licé Gegia, Medea Jaramillo, Ernesto Zignol, Matteo Kasaeva, Tereza World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update |
title | World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update |
title_full | World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update |
title_fullStr | World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update |
title_full_unstemmed | World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update |
title_short | World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update |
title_sort | world health organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update |
topic | Task Force Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176349/ https://www.ncbi.nlm.nih.gov/pubmed/33243847 http://dx.doi.org/10.1183/13993003.03300-2020 |
work_keys_str_mv | AT mirzayevfuad worldhealthorganizationrecommendationsonthetreatmentofdrugresistanttuberculosis2020update AT vineykerri worldhealthorganizationrecommendationsonthetreatmentofdrugresistanttuberculosis2020update AT linhnguyennhat worldhealthorganizationrecommendationsonthetreatmentofdrugresistanttuberculosis2020update AT gonzalezangulolice worldhealthorganizationrecommendationsonthetreatmentofdrugresistanttuberculosis2020update AT gegiamedea worldhealthorganizationrecommendationsonthetreatmentofdrugresistanttuberculosis2020update AT jaramilloernesto worldhealthorganizationrecommendationsonthetreatmentofdrugresistanttuberculosis2020update AT zignolmatteo worldhealthorganizationrecommendationsonthetreatmentofdrugresistanttuberculosis2020update AT kasaevatereza worldhealthorganizationrecommendationsonthetreatmentofdrugresistanttuberculosis2020update |